Sector News

Lilly appoints Philip Johnson to Senior Vice President and Treasurer

November 14, 2017
Life sciences

Eli Lilly and Company has announced Philip Johnson has been appointed to senior vice president, Finance, and treasurer effective January 1, 2018.

Johnson currently serves as vice president for Investor Relations at Lilly. He will report to Joshua Smiley, who will become senior vice president and chief financial officer effective January 1, 2018. Johnson will continue to lead Lilly’s investor relations efforts.

“Phil has been a trusted partner for our shareholders, effectively communicating the company’s results and expectations, while ensuring management’s actions are informed by shareholder input,” Smiley said. “With his external focus and experience in the capital markets, Phil is an ideal candidate to assume this important position and to help guide Lilly’s financial strategy.”

Johnson has been with Lilly 22 years, serving in a variety of financial roles in the U.S. and overseas. He has been in his current role since 2007 and before that was vice president, Finance, and chief financial officer for Global Manufacturing and Quality. Prior to joining Lilly, Johnson worked for six years in investment banking and management consulting in the U.S. and Europe.

Source: Eli Lilly and Company

comments closed

Related News

March 19, 2023

Ferring Pharmaceuticals’ 1st in class C.diff Treatment, Rebyota, experiences a positive early launch ahead of potential competition

Life sciences

With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.

March 19, 2023

UCB enters drug discovery collaboration with Aitia

Life sciences

Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.

March 19, 2023

Novo, Medtronic add $25M in fuel to FIRE1 and its heart failure monitoring device

Life sciences

Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.

How can we help you?

We're easy to reach